Anergis (Switzerland) a clinical-stage biopharmaceutical company focused on immunotherapies against allergies, closed announced today that it has closed a $14.3M Series A financing. Participants include Vinci Capital, BioMedInvest, Sunstone Capital, Esperante Ventures and Initiative Capital Romandie.
Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb
Jado Technologies (Germany) early-stage developer of small molecule allergy and antiinfective therapeutics, closed a $4.9M Series B financing. Participants include Peppermint Financial Partners, NRW Bank, Dresden Fonds, EMBL Ventures, ERP-Startfonds, Max Planck Society and MASA Life Science Ventures.
RegImmune (Mountain View, CA) early-stage biopharmaceutical company focused on the treatment of graft versus host disease, allergies, autoimmune diseases and other inflammatory diseases, closed a $8M Series B financing. Participants include NIF SMBC Ventures, CSK Venture Capital, Japan Asia Investment Co, and Yasuda Enterprise Development Co.